News Release

A flexible fix for rigid stents

University of Pittsburgh startup EV2 Technologies receives $2.1M award to advance PAD treatment

Grant and Award Announcement

University of Pittsburgh

Mockup of the Biocarpet device deployed in a tortuous artery

image: 

Mockup of the Biocarpet device deployed in a tortuous artery

view more 

Credit: EV2 Technologies

Peripheral artery disease (PAD) is present in more than 12 million Americans and 200 million individuals worldwide. The demand for advanced treatment is rising fast — and a University of Pittsburgh-based startup was just awarded funding to help meet it.

EV2 Technologies, Inc., received a two-year, $2.1 million Small Business Innovation Research Direct-to-Phase II (SBIR) award from the National Institutes of Health (NIH) National Heart Lung and Blood Institute (NHLBI) for their innovative device, Biocarpet, a fully biodegradable sheet that unfurls inside blood vessels to relieve dangerous blockages caused by PAD. While stents are commonly used to treat the disease, these devices are not compatible with small or winding arteries and often fail after they are implanted, particularly in vessels that cross joints. 

"Our goal is to provide patients with an improved endovascular treatment option," said Jonathan Vande Geest, EV2 co-founder and professor of bioengineering at the Swanson School of Engineering. "Blood vessels aren't just straight tubes, and as we age, they can become a very complex biomechanical environment. We invented Biocarpet to provide a solution that conforms to this complicated vascular anatomy and reduces the likelihood of restenosis."

EV2 Technologies grew out of years of research by a team of co-founders, including CEO & principal investigator Ali Behrangzade (BioE PhD ‘22), William R. Wagner, Distinguished Professor of Bioengineering, John Pacella, associate professor at Pitt's School of Medicine and UPMC interventional cardiologist, and Vande Geest. Over the next two years, the award will fund several parallel efforts. 

The team will refine its manufacturing process to lay the foundation for scalability. They'll also redesign the thermal balloon catheter used to deliver the device, and work on designing a control console that can be compatible with any catheterization laboratory. Alongside those engineering updates, the company will run a wide range of benchtop testing on the improved prototypes, followed by the six-month study to assess the device's safety and efficacy in an animal model.

The technology’s path to this point has been years in the making. In 2019, Pitt’s Center for Medical Innovation (CMI) awarded the team funding to demonstrate feasibility on the bench, which helped lay the groundwork for follow-on funds and big wins at the Wells Student HealthTech Challenge, the Randall Family Big Idea Center Pitch Competition, and Pitt Innovation Challenge (PInCh) competitions.

Behrangzade joined the department’s faculty in 2022 and began working full time on Biocarpet, supported by PInCh and other funding sources. That position gave him the footing to generate data in collaboration with colleagues across the department, which became the foundation for the company’s SBIR application. In 2023, Vande Geest received an NIH Catalyze grant for the project, with Behrangzade serving as co-investigator and team lead. 

The Catalyze funding allowed the team to bypass the traditional Phase I SBIR process, and the data it produced ultimately led to the successful application for the Direct-to-Phase II SBIR award now funding the company’s current work.

“Without support from the Office for Innovation and Entrepreneurship (OIE), CMI, the McGowan Institute for Regenerative Medicine, LifeX, NHLBI, and more, this technology wouldn’t be where it is today,” Vande Geest said. “Each one of these programs gave us something we needed at exactly the right moment, from that first bit of funding to attracting this opportunity now.”

The award also marks a turning point for EV2: for the first time, the company has the resources to formally license the underlying technology from the University. “Given the nature of our work, we’re pursuing a hybrid approach between private and federal fundraising,” Behrangzade said. “We’re still going to be looking for more grants, and at the same time, connecting with VCs to explore potential funding opportunities in that sector.”


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.